|
**Overview**: Allergy Dust Panel**Introduction**: The Allergy Dust Panel is a diagnostic tool designed to screen for dust allergies using serum samples. In India, dust mite and cockroach allergens are dominant indoor triggers, with sensitization rates of 47-93 percent for house dust mite and 18-40 percent for cockroach in allergic rhinitis/asthma patients. These allergens are prevalent due to high humidity, overcrowding, poor ventilation in urban slums and rural homes, and seasonal monsoons. Symptoms include persistent rhinitis, asthma exacerbations, nocturnal coughing, and eye irritation. High morbidity from underdiagnosis in children and adults in low-SES households, limited access to testing, and overlap with viral infections. Per immunology practices (aligned ICMR guidelines), the test employs immunoassay for detailed parameter analysis over 1-2 days with high sensitivity/specificity, valuable for identifying major indoor triggers in persistent respiratory cases. This diagnostic falls under allergy screening and targets individuals with suspected dust allergies, addressing accurate detection to guide environmental control measures and pharmacotherapy. With morbidity elevated due to underdiagnosis in densely populated areas, the test supports public health efforts by enabling precise identification, facilitating management, and reducing chronic symptoms and exacerbations. Its serum-based approach ensures reliable detection in India's varied environmental and lab settings.**Other Names**: Dust Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded with specific IgE testing; in India, prominence due to dust mite and cockroach dominance in indoor allergen profiles.**Purpose**: The test screens for 4 parameters including house dust mite IgE to guide dust allergy assessment, identify key triggers, and inform avoidance/treatment strategies.**Test Parameters**: 1. House Dust Mite IgE, 2. Cockroach IgE, 3. Dust Mix IgE, 4. Total IgE.**Pretest Condition**: No fasting required; patients should report persistent rhinitis, nocturnal asthma symptoms, or worsening in dusty environments.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on home environment (dust, pests, ventilation), symptom patterns, family allergy history, or urban/rural residence.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated allergies including chronic respiratory issues, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent viral infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible dust allergy, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Allergists or pulmonologists should be consulted for case management, environmental control planning, and coordination with health programs.**Additional Supporting Tests**: Home dust sampling or environmental assessment for confirmation.**Test Limitations**: The test may produce false negatives in low exposure or false positives in sensitization without clinical disease, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Indian Journal of Allergy Asthma Immunology 2024, Dust Allergen Studies India 2023. |
